阿柏西普联合放疗及同期和辅助替莫唑胺治疗高级别胶质瘤的I期试验
成人脑肿瘤联盟开展I期试验,采用3+3设计,评估阿柏西普联合放疗及同期和辅助替莫唑胺治疗新诊断高级别胶质瘤。共入组59例,分3组,阿柏西普最大耐受剂量为每2周4 mg/kg,达到主要终点。
要点
- 阿柏西普联合放疗及替莫唑胺的最大耐受剂量为每2周4 mg/kg。
- 59例患者中,第1组21例、第2组20例、第3组18例。
- 中位阿柏西普周期数为5(范围1-16)。
核心结论
- 本研究达到主要终点,阿柏西普联合放疗及同期和辅助替莫唑胺的最大耐受剂量为每2周4 mg/kg。
研究设计与样本
- 成人脑肿瘤联盟开展I期试验,采用3+3设计,设2个剂量水平,评估阿柏西普联合替莫唑胺治疗新诊断高级别胶质瘤。
- 共入组59例患者,第1组21例(联合放疗及同期替莫唑胺),第2组20例(联合辅助替莫唑胺5/28方案),第3组18例(联合辅助替莫唑胺21/28天方案)。
- 中位年龄56岁(范围24-69),中位KPS 90(范围60-100)。
主要发现
- 所有3组阿柏西普的最大耐受剂量均为每2周4 mg/kg。
- 最大耐受剂量下剂量限制性毒性:第1组0/21例,第2组2/20例(3级深静脉血栓、4级中性粒细胞减少),第3组3/18例(4级活检证实的血栓性微血管病、3级皮疹、4级血小板减少)。
- 中位阿柏西普周期数为5(范围1-16)。
- 所有患者均停止治疗;28例(47%)因疾病进展,21例(36%)因毒性,8例(14%)因其他原因,2例(3%)完成全疗程。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-vascular endothelial growth factor (VEGF) therapy has shown promise in the treatment of high-grade gliomas (HGG). Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for VEGF-A, VEGF-B and placental growth factor, depleting circulating levels of these growth factors. The Adult Brain Tumor Consortium conducted a phase I trial of aflibercept and temozolomide (TMZ) in patients with newly diagnosed HGG with 2 dose levels and a 3+3 design. Three arms using aflibercept were examined; with radiation and concomitant temozolomide; with adjuvant temozolomide using the 5/28 regimen; and with adjuvant temozolomide using the 21/28 day regimen. Fifty-nine patients were enrolled, 21 in arm 1, 20 in arm 2 and 18 in arm 3. Median age was 56 years (24-69); median KPS 90 (60-100). The maximum tolerated dose (MTD) of aflibercept for all 3 arms was 4 mg/kg every 2 weeks. Dose limiting toxicities at the MTD were: Arm 1: 0/21 patients; Arm 2: 2/20 patients (G3 deep vein thrombosis, G4 neutropenia; Arm 3: 3/18 patients) (G4 biopsy-confirmed thrombotic microangiopathy, G3 rash, G4 thrombocytopenia). The median number of cycles of aflibercept was 5 (range, 1-16). All patients stopped treatment; 28 (47%) for disease progression, 21 (36%) for toxicities, 8 (14%) for other reasons, and 2 (3%) patients completed the full treatment course. This study met its primary endpoint and the MTD of aflibercept with radiation and concomitant and adjuvant temozolomide is 4 mg/kg every 2 weeks.
引用
- Nayak L, de Groot J, Wefel JS, et al. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017. PMID: 28116649. doi:10.1007/s11060-016-2357-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。